phase ii results for cabozantinib in ret-rearranged lung cancer
Published 7 years ago • 279 plays • Length 1:12Download video MP4
Download video MP3
Similar videos
-
1:36
dr. reckamp on cabozantinib plus erlotinib for advanced egfr-mutant nsclc
-
3:21
cabosun trial: cabozantinib vs sunitinib for renal cell carcinoma
-
1:52
belzutifan cabozantinib combo shows durable anti-tumour effect at phase ii for ccrcc
-
2:12
results of a trial comparing cabozantinib and sunitinib in mrcc
-
3:56
phase ii trial of pembrolizumab & cabozantinib in patients with recurrent metastatic hnscc
-
3:32
ret in lung cancer: the next big target?
-
26:57
segment 2: molecular targets in nsclc
-
2:02
cabozantinib in mrcc
-
3:22
status and potential utility of cabozantinib in lung cancer?
-
1:20
promising results of cabozantinib plus nivolumab in non-clear cell rcc
-
1:07
dr. rekamp discusses a phase ii study mk-2206 plus erlotinib in nsclc
-
3:49
ret fusion treatment: selpercatinib - targeted therapies in lung cancer 2023
-
![lung cancer targeted gene panel with rearrangement [a test in focus]](https://i.ytimg.com/vi/3di7BoVAkn0/mqdefault.jpg)
3:30
lung cancer targeted gene panel with rearrangement [a test in focus]
-
3:18
arrow update confirms pralsetinib benefit for ret fusion-positive advanced nsclc | stephen liu
-
27:47
ret fusion-positive nsclc: delivering targeted treatment | panel discussion
-
0:54
phase ib/ii trial of 177lu-girentuximab with cabozantinib and nivolumab in clear cell rcc
-
18:23
2021 west oncology | lung cancer | targeted therapies
-
22:44
grace targeted therapies lung cancer 2021 - new therapies: ntrk, ret and her2
-
8:23
dr nandini menon | cabozantinib c plus atezolizumab a or c alone in patients pts with advanced